Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.45
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.45
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.15 - $4.69
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$12.79M
Enterprise Value$6.08
Total Cash (Recent Filing)$17.35M
Total Debt (Recent Filing)$9.07M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding4,368,295
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.72M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue & MarginsHaving an approved product (APHEXDA) generating recurring royalties and strong gross margins (~74.7%) provides durable unit economics. Even modest, repeatable royalty streams validate commercialization and create a base revenue line that supports R&D and partnership optionality over the next 2–6 months.
Advancing Clinical-stage PipelineFirst-in-human dosing and BBB-penetrant preclinical efficacy materially de‑risk GLIX1 as a platform asset. If GLIX1 shows tolerability and signals in GBM or in combo with PARP inhibitors, the program can shift BioLineRx from a royalty-dependent firm to one with higher upside optionality and sustainable pipeline-driven growth.
Partner-led Commercialization And Retained RightsStrategic licensing with Ayrmid and retained PDAC rights balance risk and upside: partners scale commercialization and fund launches while BioLineRx keeps key indications. This model reduces capex and commercial burn, preserves upside via royalties/milestones, and supports focus on high‑value clinical development.
Bears Say
Negative Cash GenerationSustained negative operating and free cash flow indicates the business is not self-financing its development and commercial activities. Over several quarters this increases reliance on external capital, creates dilution risk, and constrains timing and scale of trials or commercial investments if additional funding is delayed.
Short Cash RunwayA runway into roughly H1 2027 means key GLIX1 dose‑escalation results and expansion decisions may require financing before value-inflecting readouts. The need to raise capital ahead of pivotal data can force dilutive financings or preemptive partnerships, reducing strategic flexibility and shareholder upside.
Commercial Dependence & Limited DisclosureHeavy dependence on a partner for commercialization and lack of operational transparency limit visibility into future royalty growth, market penetration and supply execution. Over time this can slow revenue scaling, complicate forecasting, and transfer execution risk outside the company’s control, weakening durable revenue predictability.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $4.69 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $12.79M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Aug 13, 2026 which is in 20 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on May 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.15.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,368,295 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 6.646%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
BLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(389.80% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors